These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30617953)

  • 41. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
    Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
    Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
    Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
    Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
    Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How long has NICE taken to produce Technology Appraisal guidance? A retrospective study to estimate predictors of time to guidance.
    Casson SG; Ruiz FJ; Miners A
    BMJ Open; 2013 Jan; 3(1):. PubMed ID: 23315516
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
    Towse A; Pritchard C
    Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.
    Dietrich ES
    Int J Technol Assess Health Care; 2009 Jul; 25(3):262-71. PubMed ID: 19619344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
    Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
    Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decision making by NICE: examining the influences of evidence, process and context.
    Cerri KH; Knapp M; Fernández JL
    Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ponatinib for Treating Chronic Myeloid Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Pandor A; Stevenson M; Stevens J; James MM; Hamilton J; Byrne J; Rudin C; Rawdin A; Wong R
    Pharmacoeconomics; 2018 Aug; 36(8):903-915. PubMed ID: 29480454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Duarte R; Richardson M; Nevitt S; Boland A; Kotas E; McEntee J; Thorp N
    Pharmacoecon Open; 2019 Sep; 3(3):293-302. PubMed ID: 30742256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.
    Llewellyn A; Faria R; Woods B; Simmonds M; Lomas J; Woolacott N; Griffin S
    Pharmacoeconomics; 2016 Oct; 34(10):981-92. PubMed ID: 27278217
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Fleeman N; Bagust A; Boland A; Beale S; Richardson M; Krishan A; Stainthorpe A; Abdulla A; Kotas E; Banks L; Payne M
    Pharmacoeconomics; 2017 Oct; 35(10):1035-1046. PubMed ID: 28316007
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Benefits of probabilistic sensitivity analysis - a review of NICE decisions.
    Adalsteinsson E; Toumi M
    J Mark Access Health Policy; 2013; 1():. PubMed ID: 27226828
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ledipasvir-Sofosbuvir for Treating Chronic Hepatitis C: A NICE Single Technology Appraisal-An Evidence Review Group Perspective.
    Thokala P; Simpson EL; Tappenden P; Stevens JW; Dickinson K; Ryder S; Harrison P
    Pharmacoeconomics; 2016 Aug; 34(8):741-50. PubMed ID: 26892974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.